Solid Biosciences Inc. (SLDB)
| Market Cap | 733.04M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -174.33M |
| Shares Out | 98.39M |
| EPS (ttm) | -1.99 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 690,584 |
| Open | 7.49 |
| Previous Close | 7.50 |
| Day's Range | 7.37 - 7.66 |
| 52-Week Range | 2.41 - 8.87 |
| Beta | 2.58 |
| Analysts | Strong Buy |
| Price Target | 16.36 (+119.6%) |
| Earnings Date | May 14, 2026 |
About SLDB
Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company’s lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, which is in preclinical phase; SGT-401 for the treat... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for SLDB stock is "Strong Buy." The 12-month stock price target is $16.36, which is an increase of 119.60% from the latest price.
News
Solid Biosciences Announces Receipt of European Commission Orphan Drug Designation for SGT-003 for the Treatment of Duchenne Muscular Dystrophy
- Orphan drug designation from the European Commission underscores Solid's commitment to advance SGT-003 through a global development effort for individuals living with Duchenne muscular dystrophy - ...
Solid Biosciences Transcript: 25th Annual Needham Virtual Healthcare Conference
The presentation highlighted robust clinical and biomarker data for DMD and FA gene therapy programs, emphasizing unique capsid design, strong safety, and early functional improvements. Plans include expanding cardiac programs, licensing next-gen capsids, and a major FA data readout by year-end.
Solid Biosciences to Participate at Upcoming Investor Conferences
CHARLESTOWN, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscula...
Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
- Duchenne (SGT-003): Positive interim Phase 1/2 INSPIRE DUCHENNE data reported at the 2026 MDA Annual Meeting continued to suggest differentiated clinical, safety and tolerability profiles; SGT-003 h...
Solid Biosciences Transcript: Barclays 28th Annual Global Healthcare Conference
SGT-003 for DMD shows strong safety, high expression, and promising cardiac efficacy in early trials. Regulatory strategy includes FDA-aligned data disclosure and a global Phase III trial, with commercialization plans supported by a $240M cash runway and ILAP status in the UK.
Solid Biosciences Touts Encouraging Results For Duchenne Gene Therapy, FDA Talks Planned
Solid Biosciences Inc. (NASDAQ: SLDB) shares are tumbling on Wednesday following a recent update regarding the company's clinical trial for SGT-003, an investigational gene therapy.
Solid Biosciences Provides Interim Positive Clinical Update on Phase 1/2 INSPIRE DUCHENNE Trial
- 40 participants have been dosed with SGT-003 in the INSPIRE DUCHENNE trial to date - - Robust microdystrophin expression with consistent mechanistic evidence of dystrophin associated protein complex...
Solid Biosciences Announces Oversubscribed $240 Million Private Placement
CHARLESTOWN, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, tod...
Solid Biosciences to Present at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
CHARLESTOWN, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, tod...
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CHARLESTOWN, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardi...
Solid Biosciences Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
The company is advancing gene therapies for DMD and FA, with FDA-aligned trials and innovative delivery platforms. DMD trials show a strong safety profile and optimized steroid use, while the FA program uses precise dual-route administration. Initial FA data is expected later this year.
Solid Biosciences Announces Positive Feedback from Type C Meeting with FDA for SGT-003 Gene Therapy for Duchenne Muscular Dystrophy
- IMPACT DUCHENNE: Company aligned with FDA on Phase 3 randomized, double-blind, placebo-controlled trial design - - IMPACT DUCHENNE: Company anticipates first participant dosing in Q1 2026 - - Compan...
Solid Biosciences to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
CHARLESTOWN, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular...
Solid Biosciences Transcript: 44th Annual J.P. Morgan Healthcare Conference
Significant progress was reported across clinical programs, including full enrollment of a global Duchenne trial, first-in-human dual-route dosing in FA, and robust safety and biomarker data. Regulatory milestones and a midyear data update are expected to drive major inflection points.
Solid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to Next-Generation Capsid AAV-SLB101
- Duchenne: Dosed 33 participants in the Phase 1/2 INSPIRE DUCHENNE clinical trial as of January 9, 2026; SGT-003 continues to be generally well tolerated using a steroid-only prophylactic immunomodu...
Solid Biosciences Receives FDA Orphan Drug Designation for SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich's Ataxia
- SGT-212 has received FDA Fast Track, Rare Pediatric Disease and Orphan Drug designations - - Dosing of the first participant in the Phase 1b FALCON trial has been completed, with initial data expect...
Solid Biosciences Doses First Participant in First-in-Class Phase 1b FALCON Trial Evaluating SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich's Ataxia
Initial data from the Phase 1b FALCON trial expected in H2 2026, subject to participant enrollment Initial data from the Phase 1b FALCON trial expected in H2 2026, subject to participant enrollment
Solid Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
CHARLESTOWN, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular...
Solid Biosciences Announces Duchenne Muscular Dystrophy Added to National Recommended Uniform Screening Panel by the U.S. Department of Health and Human Services
CHARLESTOWN, Mass., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular...
Solid Biosciences to Showcase Proprietary Next-Generation Capsid AAV-SLB101 and Cardiac Gene Therapy Pipeline at the 22nd Global CardioVascular Clinical Trialists (CVCT) Forum
CHARLESTOWN, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular...
Solid Biosciences Transcript: Piper Sandler 37th Annual Healthcare Conference
The company is advancing a next-generation gene therapy platform with a novel capsid, focusing on DMD, FA, and CPVT. Regulatory discussions are planned for early 2024, with multiple cohorts enrolled and promising early safety and efficacy data. Initial FA dosing is set for January, with data updates expected soon.
Solid Biosciences Receives FDA Rare Pediatric Disease Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich's Ataxia
– SGT-212 has been granted FDA Rare Pediatric Disease and Fast Track designations – – SGT-212 is the only dual route gene therapy in development to treat Friedreich's ataxia – – FALCON Phase 1b clinic...
Solid Biosciences Announces Licensing Agreement with Andelyn Biosciences for the Use of Proprietary Next-Generation Capsid AAV-SLB101
- Non-exclusive license providing Solid's proprietary, next-generation capsid, AAV-SLB101, to Andelyn Biosciences, a full-service cell and gene therapy Contract Development and Manufacturing Organizat...
Solid Biosciences Awarded Innovation Passport Designation Under the New UK Innovative Licensing and Access Pathway for SGT-003, an Investigational Gene Therapy for Duchenne Muscular Dystrophy
- Innovation Passport award facilitates accelerated time to market and helps expedite patient access to transformative new medicines -
Solid Biosciences Reports Third Quarter 2025 Financial Results and Provides Update on INSPIRE DUCHENNE Clinical Trial Progress and Planned Regulatory Discussions
- Duchenne (SGT-003): 23 participants have been dosed in the INSPIRE DUCHENNE trial as of October 31, 2025; Solid expects to have dosed 30 participants in total by early 2026, then plans to meet with...